B
Bull
Bull · 25%GNTA
$4.84
Szenariopreis
$1.010
-0.010 (-0.98%)Zum Schluss
Loading chart…
- High
- 1.020
- Open
- 1.000
- VWAP
- 1.01
- Vol
- 30.08K
- Mkt Cap
- 56.65M
- Low
- 1.000
- Amount
- 30.38K
- EV/EBITDA, TTM
- 0.00
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
AI analysis of Genenta Science SPA (GNTA)
holdGiven the current price of $1.00 and the RSI of 20.266 indicating oversold conditions, GNTA may present a potential buying opportunity in the long term. However, the significant 1-year change of -71.65% raises concerns about the company's stability and market performance.
Bewertungskennzahlen
The current forward P/E ratio for Genenta Science SPA (GNTA) is 0.00, compared to its 5-year average forward P/E of -8.73.
Alphio AI Price Scenarios for GNTA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
3.507-23NewsfilterSòphia HT Unveils ROMAN Robotic Arm for Nuclear Fusion Maintenance
- 9.507-22Newsfilter
Sòphia HT Reports Significant Growth in FY2025 Financials
8.504-23seekingalphaGenenta Science Acquires Majority Stake in Sòphia High Tech
- 8.503-27Newsfilter
Genenta Acquires Sòphia High Tech to Advance Strategic Consolidation
8.503-13Yahoo FinanceGenenta Science Transforms to Saentra Forge, Focused on Strategic Industrial Consolidation
GNTA FAQ — answered by Alphio AI
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States. It operates in the Healthcare sector.
Given the current price of $1.00 and the RSI of 20.266 indicating oversold conditions, GNTA may present a potential buying opportunity in the long term. However, the significant 1-year change of -71.65% raises concerns about the company's stability and market performance.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.